- |||||||||| PF-07284892 / Pfizer
Trial completion date, Trial termination, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Oct 16, 2024
P1, N=53, Terminated,
Trial completion date: Nov 2025 --> Jun 2024 | Active, not recruiting --> Terminated; The study was prematurely discontinued due to strategic reasons. The PF-07284892 program will continue
- |||||||||| PF-07284892 / Pfizer
Enrollment closed, Enrollment change, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 28, 2023
P1, N=36, Active, not recruiting,
N=36 --> 53 Recruiting --> Active, not recruiting | N=196 --> 36
- |||||||||| PF-07284892 / Pfizer
Journal: SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. (Pubmed Central) - Aug 7, 2023
PF-07284892 (ARRY-558) is an allosteric SHP2 inhibitor designed to overcome bypass-signaling-mediated resistance when combined with inhibitors of various oncogenic drivers...This provides proof of concept of the utility of SHP2 inhibitors in overcoming resistance to diverse targeted therapies and provides a paradigm for accelerated testing of novel drug combinations early in clinical development. See related commentary by Hernando-Calvo and Garralda.
- |||||||||| PF-07284892 / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jul 21, 2023
P1, N=196, Recruiting,
(7). Trial completion date: Sep 2026 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Jun 2024
- |||||||||| PF-07284892 / Pfizer
Trial completion date, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2023
P1, N=196, Recruiting,
Trial completion date: Sep 2026 --> Dec 2025 | Trial primary completion date: Jun 2025 --> Jun 2024 Trial completion date: Apr 2026 --> Sep 2026
- |||||||||| PF-07284892 / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 2, 2023
P1, N=196, Recruiting,
Clinical trial information: NCT04800822. Trial completion date: Feb 2027 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Apr 2025
- |||||||||| PF-07284892 / Pfizer
Enrollment change, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 18, 2021
P1, N=211, Recruiting,
Trial completion date: Feb 2027 --> Apr 2026 | Trial primary completion date: Feb 2026 --> Apr 2025 N=70 --> 211
|
